Literature DB >> 1642643

Stereoselective interactions of ketoprofen glucuronides with human plasma protein and serum albumin.

P J Hayball1, R L Nation, F Bochner.   

Abstract

A clearance pathway common to many aryl alkanoic acids is the generation of renally eliminated ester glucuronides. These metabolites are susceptible to systemic hydrolysis which generates the parent aglycone. We have conducted in vitro studies with biosynthetic R- and S-ketoprofen glucuronides to elucidate the mechanism of this phenomenon. These conjugates were incubated in human plasma, various concentrations of human serum albumin (HSA) and protein-free buffer. It was apparent that albumin, rather than plasma esterases, catalysed the hydrolysis of the glucuronides. The albumin-catalysed hydrolysis of ketoprofen glucuronides was highly stereoselective. The mean (+/- SD) hydrolysis half-life of R-ketoprofen glucuronide in plasma (N = 4) at physiological pH and temperature was 1.37 (+/- 0.30) hr. The corresponding value for S-ketoprofen glucuronide, 3.46 (+/- 0.84) hr, was significantly different (P less than 0.005). In contrast, synthetic ethyl esters of R- and S-ketoprofen were hydrolysed by plasma esterases, but not by HSA, and with little stereoselectivity. The reversible protein binding of ketoprofen glucuronides was determined at physiological pH and temperature by a rapid ultra-filtration method. The binding of R- and S-ketoprofen glucuronide to human plasma protein was independent of concentration (P greater than 0.05) over the range of 1-20 micrograms/mL. The mean (+/- SD) percentage unbound in plasma (N = 4) of R-ketoprofen glucuronide was 12.6 (+/- 1.4)%. The corresponding value for S-ketoprofen glucuronide, 9.12 (+/- 0.54)%, was significantly different (P less than 0.005). S-Ketoprofen glucuronide was also more avidly protein bound in physiological concentrations of HSA. However, this stereoselectivity decreased in more dilute HSA solutions. Based on the hydrolysis and protein binding data for ketoprofen glucuronides, we propose the existence of separate binding and catalytic sites on the albumin molecule for these metabolites.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1642643     DOI: 10.1016/0006-2952(92)90012-8

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  7 in total

Review 1.  Preclinical and clinical development of dexketoprofen.

Authors:  D Mauleón; R Artigas; M L García; G Carganico
Journal:  Drugs       Date:  1996       Impact factor: 9.546

2.  Stereoselective pharmacokinetics of ketoprofen and ketoprofen glucuronide in end-stage renal disease: evidence for a 'futile cycle' of elimination.

Authors:  N G Grubb; D W Rudy; D C Brater; S D Hall
Journal:  Br J Clin Pharmacol       Date:  1999-10       Impact factor: 4.335

3.  The influence of renal function on the enantioselective pharmacokinetics and pharmacodynamics of ketoprofen in patients with rheumatoid arthritis.

Authors:  P J Hayball; R L Nation; F Bochner; L N Sansom; M J Ahern; M D Smith
Journal:  Br J Clin Pharmacol       Date:  1993-09       Impact factor: 4.335

4.  Stereoselective hepatic disposition of model diastereomeric acyl glucuronides.

Authors:  David M Shackleford; Roger L Nation; R W Milne; P J Hayball; Allan M Evans
Journal:  J Pharmacokinet Pharmacodyn       Date:  2004-02       Impact factor: 2.745

5.  Reversible binding of tolmetin, zomepirac, and their glucuronide conjugates to human serum albumin and plasma.

Authors:  J C Ojingwa; H Spahn-Langguth; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1994-02

6.  Pollutant-induced modulation in conformation and β-lactamase activity of human serum albumin.

Authors:  Ejaz Ahmad; Gulam Rabbani; Nida Zaidi; Basir Ahmad; Rizwan Hasan Khan
Journal:  PLoS One       Date:  2012-06-07       Impact factor: 3.240

7.  Stereoselective Covalent Adduct Formation of Acyl Glucuronide Metabolite of Nonsteroidal Anti-Inflammatory Drugs with UDP-Glucuronosyltransferase.

Authors:  Atsushi Kawase; Rio Yamashita; Tsubasa Yoshizato; Mashiro Yoshikawa; Hiroaki Shimada; Masahiro Iwaki
Journal:  Int J Mol Sci       Date:  2022-04-25       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.